Amylyx Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0.0 | $87.4 | $380.8 | $22.2 | $0.3 |
| Operating income | -$153.3 | -$314.7 | $38.8 | -$201.3 | -$82.7 |
| Net income | -$144.7 | -$301.7 | $49.3 | -$198.4 | -$87.9 |
| Cash Flow Statement | |||||
| Free cash flow | -$123.5 | -$167.8 | $10.7 | -$182.4 | -$75.2 |
Shares outstanding 111.4M · Free float 79.8%
Annual filing data through FY ended December 31, 2025; float as of October 3, 2026.